Biotronik’s Orsiro stent shows equivalent performance to alternative devices

Biotronik has announced the findings of a new study showing how its Orsiro hybrid drug-eluting stent offers similar performance to alternative products.

The BIO-RESORT trial assessed 3,514 subjects in an all-comers population with coronary artery disease, showing that Orsiro offered a non-inferior performance to the competing Resolute Integrity stent, as well as outcomes similar to the Synergy stent.

Its primary endpoint was target vessel failure at one year, a metric measured by assessing rates of cardiac death, target vessel-related myocardial infarction and target vessel revascularisation.

The patient group included a high proportion of almost 70 percent of acutely diseased patients, including diabetics and heart attack patients, while the rate of patients with ST-elevation myocardial infarction was extremely high at over 30 percent.

Dr Alexander Uhl, vice-president for marketing at Biotronik's vascular intervention division, said: "Orsiro has now proven non-inferior to all major competitors across a variety of indications, giving physicians confidence to use our highly deliverable DES for the treatment of coronary artery disease in diverse clinical settings."

The Orsiro stent was launched in 2011 and utilises a combination of passive and active components to deliver enhanced performance.

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.